Natco Pharma submits abbreviated new drug application with USFDA for generic cancer drug
The drug firm believes it is the first company to have filed a substantially-complete ANDA containing a Paragraph IV Certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of potential launch of the product under certain circumstances.
As per industry estimates, Tabrecta recorded sales of USD 126 million in the US market for the year 2023. Image: Pixabay/Representational